236 related articles for article (PubMed ID: 19381453)
21. Management of the new patient with CML in chronic phase.
Marin D
Curr Hematol Malig Rep; 2013 Mar; 8(1):37-42. PubMed ID: 23381448
[TBL] [Abstract][Full Text] [Related]
22. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
23. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
[TBL] [Abstract][Full Text] [Related]
25. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
27. Optimizing second-line therapy for chronic myeloid leukemia.
Raja T
Indian J Cancer; 2012; 49(1):46-56. PubMed ID: 22842168
[TBL] [Abstract][Full Text] [Related]
28. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
Goulden S; Sutcliffe F; Stevens A
Lancet Oncol; 2012 Feb; 13(2):127-8. PubMed ID: 22403810
[No Abstract] [Full Text] [Related]
29. [Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Saito M; Izumiyama K; Mori A; Irie T; Tanaka M; Morioka M; Saga A; Musashi M; Kato T; Meguro T; Tanino M
Rinsho Ketsueki; 2014 Jan; 55(1):130-2. PubMed ID: 24492046
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
33. [Chronic myeloid leukemia: up-to-date management].
Nakayama K; Inokuchi K
Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
[No Abstract] [Full Text] [Related]
34. The toxicities of modern targeted therapies: learning from the price of progress.
Giles FJ
Target Oncol; 2009 Apr; 4(2):65-6. PubMed ID: 19357815
[No Abstract] [Full Text] [Related]
35. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
37. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Holstein SA; Stokes JB; Hohl RJ
Leuk Res; 2009 Feb; 33(2):344-7. PubMed ID: 18835038
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
[TBL] [Abstract][Full Text] [Related]
39. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
[TBL] [Abstract][Full Text] [Related]
40. The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
Togasaki-Yoshimoto E; Shono K; Onoda M; Yokota A
Leuk Lymphoma; 2014 Feb; 55(2):453-6. PubMed ID: 23697842
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
